Theravance Biopharma (TBPH) Income towards Parent Company (2013 - 2026)
Theravance Biopharma (TBPH) reported Income towards Parent Company of -$5.0 million for Q1 2026, up 63.4% year-over-year from -$3.0 million in Q1 2025, and up 91.56% quarter-over-quarter from -$58.9 million in Q4 2025.
Theravance Biopharma (TBPH) Income towards Parent Company (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Income towards Parent Company data on file, last reported at -$5.0 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$5.0 million, up 63.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 71.9% YoY), and the FY2025 annual result was -$14.0 million, up 19.29% from the prior year.
- Income towards Parent Company rose to -$5.0 million in Q1 2026 per TBPH's latest filing, from -$58.9 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $927.1 million in Q3 2022 and troughed at -$58.9 million in Q4 2025.
- A 5-year average of $51.4 million and a median of -$8.5 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company jumped 4400.0% in 2022, then slumped 350.31% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at $3.9 million in 2022, then tumbled by 317.93% to -$8.5 million in 2023, then jumped by 377.26% to $23.5 million in 2024, then tumbled by 350.31% to -$58.9 million in 2025, then jumped by 91.56% to -$5.0 million in 2026.
- Business Quant data shows TBPH's Income towards Parent Company at -$5.0 million in Q1 2026, -$58.9 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -58.89 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.49 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | 3.89 Mn |
| Sep 30, 2022 | 927.09 Mn |
| Jun 30, 2022 | 18.38 Mn |
| Mar 31, 2022 | 15.59 Mn |
| Dec 31, 2021 | 25.78 Mn |
| Sep 30, 2021 | 20.60 Mn |
| Jun 30, 2021 | 12.45 Mn |